{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:58:00Z","timestamp":1775588280402,"version":"3.50.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40264-023-01351-y","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T10:02:18Z","timestamp":1697104938000},"page":"1133-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Adverse Drug Reactions to Opioids: A Study in a National Pharmacovigilance Database"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8230-9485","authenticated-orcid":false,"given":"Moa","family":"Gustafsson","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6279-1421","authenticated-orcid":false,"given":"Cristiano","family":"Matos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-0062","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Joaquim","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-5965","authenticated-orcid":false,"given":"Joep","family":"Scholl","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3224","authenticated-orcid":false,"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"1351_CR1","doi-asserted-by":"crossref","unstructured":"Pathan H, J Williams. Basic opioid pharmacology: an update. Br J Pain. 2012;6(1):11\u20136.","DOI":"10.1177\/2049463712438493"},{"issue":"3","key":"1351_CR2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-199819030-00002","volume":"19","author":"TA Bowdle","year":"1998","unstructured":"Bowdle TA. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. Drug Saf. 1998;19(3):173\u201389.","journal-title":"Drug Saf"},{"issue":"5 Suppl","key":"1351_CR3","first-page":"S47","volume":"29","author":"KE Oxycodone","year":"2005","unstructured":"Oxycodone KE. J Pain Symptom Manag. 2005;29(5 Suppl):S47-56.","journal-title":"J Pain Symptom Manag"},{"key":"1351_CR4","doi-asserted-by":"crossref","unstructured":"Z\u00f6llner C, Stein C. Opioids. Analgesia. 2006:31\u201363.","DOI":"10.1007\/978-3-540-33823-9_2"},{"key":"1351_CR5","unstructured":"National Institute on Drug Abuse. Prescription opioids DrugFacts. 2021. https:\/\/nida.nih.gov\/publications\/drugfacts\/prescription-opioids."},{"issue":"4","key":"1351_CR6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.neuron.2011.02.001","volume":"69","author":"HL Fields","year":"2011","unstructured":"Fields HL. The doctor\u2019s dilemma: opiate analgesics and chronic pain. Neuron. 2011;69(4):591\u20134.","journal-title":"Neuron"},{"issue":"41","key":"1351_CR7","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.2174\/138161281941131219130127","volume":"19","author":"W Leppert","year":"2013","unstructured":"Leppert W, Krajnik M, Wordliczek J. Delivery systems of opioid analgesics for pain relief: a review. Curr Pharm Des. 2013;19(41):7271\u201393.","journal-title":"Curr Pharm Des"},{"key":"1351_CR8","doi-asserted-by":"crossref","unstructured":"Packiasabapathy S, S. Sadhasivam. Gender, genetics, and analgesia: understanding the differences in response to pain relief. J Pain Res. 2018;11:2729\u201339.","DOI":"10.2147\/JPR.S94650"},{"issue":"1","key":"1351_CR9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bja\/aet127","volume":"111","author":"EJ Bartley","year":"2013","unstructured":"Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013;111(1):52\u20138.","journal-title":"Br J Anaesth"},{"issue":"4","key":"1351_CR10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/YCO.0000000000000337","volume":"30","author":"M Serdarevic","year":"2017","unstructured":"Serdarevic M, Striley CW, Cottler LB. Sex differences in prescription opioid use. Curr Opin Psychiatry. 2017;30(4):238\u201346.","journal-title":"Curr Opin Psychiatry"},{"issue":"3","key":"1351_CR11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5055\/jom.2020.0568","volume":"16","author":"S Marie Preciado","year":"2020","unstructured":"Marie Preciado S, et al. National gender differences in the prescribing of opioid medications from 2006 to 2015. J Opioid Manag. 2020;16(3):197\u2013208.","journal-title":"J Opioid Manag"},{"issue":"12","key":"1351_CR12","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2105\/AJPH.2009.180646","volume":"100","author":"CI Campbell","year":"2010","unstructured":"Campbell CI, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health. 2010;100(12):2541\u20137.","journal-title":"Am J Public Health"},{"key":"1351_CR13","doi-asserted-by":"crossref","first-page":"6358624","DOI":"10.1155\/2018\/6358624","volume":"2018","author":"A Samulowitz","year":"2018","unstructured":"Samulowitz A, et al. \u201cBrave Men\u201d and \u201cEmotional Women\u201d: a theory-guided literature review on gender bias in health care and gendered norms towards patients with chronic pain. Pain Res Manag. 2018;2018:6358624.","journal-title":"Pain Res Manag"},{"issue":"9","key":"1351_CR14","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jpain.2022.01.011","volume":"23","author":"C Amir","year":"2022","unstructured":"Amir C, et al. Test-retest reliability of an adaptive thermal pain calibration procedure in healthy volunteers. J Pain. 2022;23(9):1543\u201355.","journal-title":"J Pain"},{"issue":"1\u20132","key":"1351_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pain.2005.06.020","volume":"117","author":"JS Mogil","year":"2005","unstructured":"Mogil JS, Chanda ML. The case for the inclusion of female subjects in basic science studies of pain. Pain. 2005;117(1\u20132):1\u20135.","journal-title":"Pain"},{"key":"1351_CR16","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2019: 35 million people worldwide suffer from drug use disorders while only 1 in 7 people receive treatment. 2019. https:\/\/www.unodc.org\/unodc\/en\/frontpage\/2019\/June\/world-drug-report-2019_-35-million-people-worldwide-suffer-from-drug-use-disorders-while-only-1-in-7-people-receive-treatment.html."},{"key":"1351_CR17","unstructured":"World Health Organization. The selection and use of essential medicines: report of the WHO expert committee, 2017 (including the 20th WHO model list of essential medicines and the 6th model list of essential medicines for children). World Health Organization; 2017."},{"issue":"5","key":"1351_CR18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.annemergmed.2019.04.019","volume":"74","author":"A Cragg","year":"2019","unstructured":"Cragg A, et al. Risk factors for misuse of prescribed opioids: a systematic review and meta-analysis. Ann Emerg Med. 2019;74(5):634\u201346.","journal-title":"Ann Emerg Med"},{"issue":"10028","key":"1351_CR19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(16)00161-6","volume":"387","author":"S Berterame","year":"2016","unstructured":"Berterame S, et al. Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet. 2016;387(10028):1644\u201356.","journal-title":"Lancet"},{"issue":"9","key":"1351_CR20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/j.1532-2149.2014.496.x","volume":"18","author":"CS Zin","year":"2014","unstructured":"Zin CS, Chen LC, Knaggs RD. Changes in trends and pattern of strong opioid prescribing in primary care. Eur J Pain. 2014;18(9):1343\u201351.","journal-title":"Eur J Pain"},{"issue":"1","key":"1351_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ejp.520","volume":"19","author":"A Ruscitto","year":"2015","unstructured":"Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995\u20132010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain. 2015;19(1):59\u201366.","journal-title":"Eur J Pain"},{"issue":"10","key":"1351_CR22","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S2468-2667(19)30128-8","volume":"4","author":"GA Kalkman","year":"2019","unstructured":"Kalkman GA, et al. Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. Lancet Public Health. 2019;4(10):e498\u2013505.","journal-title":"Lancet Public Health"},{"issue":"8","key":"1351_CR23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.10223","volume":"2","author":"A Bedene","year":"2019","unstructured":"Bedene A, et al. Opioid prescription patterns and risk factors associated with opioid use in the Netherlands. JAMA Netw Open. 2019;2(8): e1910223.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"1351_CR24","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"issue":"2 Suppl","key":"1351_CR25","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","volume":"11","author":"R Benyamin","year":"2008","unstructured":"Benyamin R, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105\u201320.","journal-title":"Pain Physician"},{"issue":"2 Suppl","key":"1351_CR26","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","volume":"11","author":"AM Trescot","year":"2008","unstructured":"Trescot AM, et al. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133\u201353.","journal-title":"Pain Physician"},{"issue":"4 Suppl","key":"1351_CR27","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00002508-200207001-00002","volume":"18","author":"CE Inturrisi","year":"2002","unstructured":"Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002;18(4 Suppl):S3-13.","journal-title":"Clin J Pain"},{"issue":"4","key":"1351_CR28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s11096-018-0711-z","volume":"40","author":"P Baldo","year":"2018","unstructured":"Baldo P, Francescon S, Fornasier G. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology. Int J Clin Pharm. 2018;40(4):748\u201353.","journal-title":"Int J Clin Pharm"},{"key":"1351_CR29","unstructured":"National Institute on Drug Abuse. Misuse of prescription drugs research report. National Institute of Drug Abuse; 2020. https:\/\/nida.nih.gov\/download\/37630\/misuse-prescription-drugs-research-report.pdf?v=add4ee202a1d1f88f8e1fdd2bb83a5ef."},{"issue":"1","key":"1351_CR30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40264-017-0588-0","volume":"41","author":"RE Ferner","year":"2018","unstructured":"Ferner RE, Easton C, Cox AR. Deaths from medicines: a systematic analysis of coroners\u2019 reports to prevent future deaths. Drug Saf. 2018;41(1):103\u201310.","journal-title":"Drug Saf"},{"key":"1351_CR31","unstructured":"Frequently asked questions (FAQ): drug overdose deaths in Europe. European Monitoring Centre for Drugs and Drug Addiction; 2022."},{"issue":"5","key":"1351_CR32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000337028","volume":"18","author":"A Casati","year":"2012","unstructured":"Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res. 2012;18(5):228\u201345.","journal-title":"Eur Addict Res"},{"issue":"5","key":"1351_CR33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/bcp.12133","volume":"76","author":"I Giraudon","year":"2013","unstructured":"Giraudon I, et al. Prescription opioid abuse in the UK. Br J Clin Pharmacol. 2013;76(5):823\u20134.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1351_CR34","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/pds.1823","volume":"18","author":"K Shah","year":"2009","unstructured":"Shah K, Barker KA. Out-of-hospital medication errors: a 6-year analysis of the national poison data system. Pharmacoepidemiol Drug Saf. 2009;18(11):1080\u20135.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1351_CR35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/bcpt.12150","volume":"114","author":"O Lavon","year":"2014","unstructured":"Lavon O, Ben-Zeev A, Bentur Y. Medication errors outside healthcare facilities: a national poison centre perspective. Basic Clin Pharmacol Toxicol. 2014;114(3):288\u201392.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"e1","key":"1351_CR36","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1136\/ejhpharm-2020-002298","volume":"28","author":"A Mulac","year":"2021","unstructured":"Mulac A, et al. Severe and fatal medication errors in hospitals: findings from the Norwegian Incident Reporting System. Eur J Hosp Pharm. 2021;28(e1):e56\u201361.","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"1351_CR37","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/jcm12010194","volume":"12","author":"AM Jambrina","year":"2022","unstructured":"Jambrina AM, et al. Detection and prevention of medication errors by the network of sentinel pharmacies in a Southern European Region. J Clin Med. 2022;12(1):194.","journal-title":"J Clin Med"},{"issue":"3","key":"1351_CR38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1213\/ANE.0000000000002279","volume":"125","author":"LMY Lobaugh","year":"2017","unstructured":"Lobaugh LMY, et al. Medication errors in pediatric anesthesia: a report from the wake up safe quality improvement initiative. Anesth Analg. 2017;125(3):936\u201342.","journal-title":"Anesth Analg"},{"issue":"12","key":"1351_CR39","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2165\/11584390-000000000-00000","volume":"33","author":"HW Wang","year":"2010","unstructured":"Wang HW, et al. An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf. 2010;33(12):1117\u201333.","journal-title":"Drug Saf"},{"key":"1351_CR40","unstructured":"MedDRA. Medical dictionary for regulatory activities. Maintenance and Support Services Organization; 2022."},{"key":"1351_CR41","unstructured":"World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD index 2011. World Health Organization; 2011."},{"key":"1351_CR42","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. N02A opioids. 2023. https:\/\/www.whocc.no\/atc_ddd_index\/?code=n02a."},{"key":"1351_CR43","unstructured":"Nederland, Z., GIPdatabank. Aantal gebruikers 2013\u20132018 van Pijnstillers, 2019."},{"issue":"3","key":"1351_CR44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00787-010-0087-7","volume":"19","author":"M Szumilas","year":"2010","unstructured":"Szumilas M. Explaining odds ratios. J Can Acad Child Adolesc Psychiatry. 2010;19(3):227\u20139.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"1351_CR45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.coph.2021.02.008","volume":"57","author":"F Schifano","year":"2021","unstructured":"Schifano F, et al. The e-psychonaut drugs\u2019 psychopharmacology. Curr Opin Pharmacol. 2021;57:165\u201374.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"1351_CR46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/cns.13115","volume":"25","author":"F Schifano","year":"2019","unstructured":"Schifano F, Chiappini S. Pregabalin: a range of misuse-related unanswered questions. CNS Neurosci Ther. 2019;25(5):659.","journal-title":"CNS Neurosci Ther"},{"key":"1351_CR47","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2022: trends and developments. EMCDDA; 2023."},{"issue":"1","key":"1351_CR48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3122\/jabfm.2008.01.070071","volume":"21","author":"JE Lessenger","year":"2008","unstructured":"Lessenger JE, Feinberg SD. Abuse of prescription and over-the-counter medications. J Am Board Fam Med. 2008;21(1):45\u201354.","journal-title":"J Am Board Fam Med"},{"key":"1351_CR49","doi-asserted-by":"crossref","unstructured":"Chiappini S, F Schifano. What about \u201cpharming\u201d? Issues regarding the misuse of prescription and over-the-counter drugs. Brain Sci. 2020;10(10):736.","DOI":"10.3390\/brainsci10100736"},{"key":"1351_CR50","doi-asserted-by":"crossref","unstructured":"Chiappini S, F. Schifano. What about \u201cpharming\u201d? Issues regarding the misuse of prescription and over-the-counter drugs. MDPI; 2020. p. 736.","DOI":"10.3390\/brainsci10100736"},{"issue":"6","key":"1351_CR51","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/ph15060675","volume":"15","author":"S Chiappini","year":"2022","unstructured":"Chiappini S, et al. Pharmacovigilance signals of the opioid epidemic over 10 years: data mining methods in the analysis of pharmacovigilance datasets collecting adverse drug reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). Pharmaceuticals. 2022;15(6):675.","journal-title":"Pharmaceuticals"},{"key":"1351_CR52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fphar.2019.00046","volume":"10","author":"F Schifano","year":"2019","unstructured":"Schifano F, et al. Assessing the 2004\u20132018 fentanyl misusing issues reported to an international range of adverse reporting systems. Front Pharmacol. 2019;10:46.","journal-title":"Front Pharmacol"},{"key":"1351_CR53","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Opioids: health and social responses. Lisbon: EMCDDA; 2021."},{"key":"1351_CR54","unstructured":"Centers for Disease Control and Prevention. Assessing benefits and harms of opioid therapy. https:\/\/www.cdc.gov\/drugoverdose\/pdf\/assessing_benefits_harms_of_opioid_therapy-a.pdf."},{"key":"1351_CR55","volume-title":"Voorschrijven van opio\u00efden in de huisartsenpraktijk","author":"Y Weesie","year":"2016","unstructured":"Weesie Y, et al. Voorschrijven van opio\u00efden in de huisartsenpraktijk. Utrecht: Netherlands Institute for Health Services Research (NIVEL); 2016."},{"key":"1351_CR56","doi-asserted-by":"crossref","unstructured":"H\u00f8jsted J, Sj\u00f8gren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain. 2007;11(5):490\u2013518.","DOI":"10.1016\/j.ejpain.2006.08.004"},{"issue":"7","key":"1351_CR57","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/bcp.13923","volume":"85","author":"ST de Vries","year":"2019","unstructured":"de Vries ST, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: an explorative observational study. Br J Clin Pharmacol. 2019;85(7):1507\u201315.","journal-title":"Br J Clin Pharmacol"},{"key":"1351_CR58","doi-asserted-by":"crossref","unstructured":"Holm L, Ekman E, Jors\u00e4ter Blomgren K. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2017. 26(3):335\u201343.","DOI":"10.1002\/pds.4155"},{"issue":"10","key":"1351_CR59","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-008-0494-6","volume":"64","author":"Y Zopf","year":"2008","unstructured":"Zopf Y, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008;64(10):999\u20131004.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1351_CR60","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/009127009803801103","volume":"38","author":"C Tran","year":"1998","unstructured":"Tran C, et al. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38(11):1003\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1351_CR61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044157","volume":"11","author":"GS Lopes","year":"2021","unstructured":"Lopes GS, et al. Sex differences in type and occurrence of adverse reactions to opioid analgesics: a retrospective cohort study. BMJ Open. 2021;11(6): e044157.","journal-title":"BMJ Open"},{"issue":"5","key":"1351_CR62","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40264-020-00913-8","volume":"43","author":"ST de Vries","year":"2020","unstructured":"de Vries ST, et al. Sex differences in adverse drug reactions of metformin: a longitudinal survey study. Drug Saf. 2020;43(5):489\u201395.","journal-title":"Drug Saf"},{"issue":"7","key":"1351_CR63","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40264-018-0646-2","volume":"41","author":"C Ekhart","year":"2018","unstructured":"Ekhart C, et al. Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors. Drug Saf. 2018;41(7):677\u201383.","journal-title":"Drug Saf"},{"issue":"1","key":"1351_CR64","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1353\/hpu.2015.0009","volume":"26","author":"KA Mack","year":"2015","unstructured":"Mack KA, et al. Prescription practices involving opioid analgesics among Americans with Medicaid, 2010. J Health Care Poor Underserved. 2015;26(1):182\u201398.","journal-title":"J Health Care Poor Underserved"},{"key":"1351_CR65","unstructured":"Frenk SM, KS Porter, Paulozzi L. Prescription opioid analgesic use among adults: United States, 1999\u20132012. US Department of Health and Human Services, Centers for Disease Control and\u00a0Prevention; 2015."},{"issue":"11","key":"1351_CR66","doi-asserted-by":"crossref","first-page":"298","DOI":"10.15585\/mmwr.mm6911a5","volume":"69","author":"LZ Schieber","year":"2020","unstructured":"Schieber LZ, et al. Variation in adult outpatient opioid prescription dispensing by age and sex\u2014United States, 2008\u20132018. MMWR Morb Mortal Wkly Rep. 2020;69(11):298\u2013302.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1351_CR67","unstructured":"Johnson JL, L Greaves, R Repta. Better science with sex and gender: a primer for health research. Women's Health Res Netw. 2007."},{"issue":"1","key":"1351_CR68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0304-3959(89)90152-8","volume":"37","author":"FJ Keefe","year":"1989","unstructured":"Keefe FJ, et al. Coping with rheumatoid arthritis pain: catastrophizing as a maladaptive strategy. Pain. 1989;37(1):51\u20136.","journal-title":"Pain"},{"issue":"5","key":"1351_CR69","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpain.2010.11.003","volume":"12","author":"LP Forsythe","year":"2011","unstructured":"Forsythe LP, et al. Race and sex differences in primary appraisals, catastrophizing, and experimental pain outcomes. J Pain. 2011;12(5):563\u201372.","journal-title":"J Pain"},{"issue":"2","key":"1351_CR70","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1037\/0033-295X.84.2.191","volume":"84","author":"A Bandura","year":"1977","unstructured":"Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84(2):191.","journal-title":"Psychol Rev"},{"key":"1351_CR71","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1023\/A:1022077922593","volume":"47","author":"T Jackson","year":"2002","unstructured":"Jackson T, et al. Gender differences in pain perception: The mediating role of self-efficacy beliefs. Sex Roles. 2002;47:561\u20138.","journal-title":"Sex Roles"},{"issue":"3","key":"1351_CR72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1034\/j.1399-6576.2003.00036.x","volume":"47","author":"H Pleym","year":"2003","unstructured":"Pleym H, et al. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand. 2003;47(3):241\u201359.","journal-title":"Acta Anaesthesiol Scand"},{"key":"1351_CR73","doi-asserted-by":"crossref","unstructured":"Berkley, K.J., Sex differences in pain. Behav Brain Sci. 1997. 20(3):371\u201380 (discussion 435\u2013513).","DOI":"10.1017\/S0140525X97221485"},{"issue":"24","key":"1351_CR74","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/S0024-3205(03)00178-4","volume":"72","author":"RM Craft","year":"2003","unstructured":"Craft RM. Sex differences in drug- and non-drug-induced analgesia. Life Sci. 2003;72(24):2675\u201388.","journal-title":"Life Sci"},{"issue":"9","key":"1351_CR75","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/imj.15209","volume":"51","author":"JM Inglis","year":"2021","unstructured":"Inglis JM, et al. Documentation of adverse drug reactions to opioids in an electronic health record. Intern Med J. 2021;51(9):1490\u20136.","journal-title":"Intern Med J"},{"key":"1351_CR76","unstructured":"Napp Pharmaceuticals Ltd. OxyNorm 5 mg Hard Capsules SmPC. 1999. https:\/\/www.medicines.org.uk\/emc\/product\/3850\/smpc#UNDESIRABLE_EFFECTS. 2022."},{"key":"1351_CR77","unstructured":"Bristol Laboratories Ltd. Brimisol PR 100 mg Prolonged-Release Tablets SmPC. 2011. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/8550\/smpc#UNDESIRABLE_EFFECTS. Cited 11 Jan 2023."},{"key":"1351_CR78","unstructured":"Kyowa Kirin Ltd. Abstral 200 microgram sublingual tablets SmPC. 2008. 2022. https:\/\/www.medicines.org.uk\/emc\/product\/10265\/smpc#UNDESIRABLE_EFFECTS. Cited 2022."},{"key":"1351_CR79","unstructured":"Ethypharm UK Ltd. Actimorph 20 mg Orodispersible tablets SmPC. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/13443\/smpc#UNDESIRABLE_EFFECTS."},{"key":"1351_CR80","unstructured":"MedlinePlus. Nitroglycerin Spray. https:\/\/medlineplus.gov\/druginfo\/meds\/a615006.html. Cited 12 Oct 2022."},{"key":"1351_CR81","unstructured":"Grunenthal Ltd. Tramacet 37.5 mg\/ 325 mg film-coated tablets SmPC. 2003. 2022. https:\/\/www.medicines.org.uk\/emc\/product\/6630\/smpc#ORIGINAL. Cited 11 Jan 2023."},{"issue":"Suppl 2","key":"1351_CR82","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/j.1526-4637.2011.01311.x","volume":"13","author":"RP Yezierski","year":"2012","unstructured":"Yezierski RP. The effects of age on pain sensitivity: preclinical studies. Pain Med. 2012;13(Suppl 2):S27\u201336.","journal-title":"Pain Med"},{"key":"1351_CR83","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neubiorev.2017.01.039","volume":"75","author":"S Lautenbacher","year":"2017","unstructured":"Lautenbacher S, et al. Age changes in pain perception: a systematic-review and meta-analysis of age effects on pain and tolerance thresholds. Neurosci Biobehav Rev. 2017;75:104\u201313.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"1351_CR84","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010364","volume":"6","author":"A Fayaz","year":"2016","unstructured":"Fayaz A, et al. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open. 2016;6(6): e010364.","journal-title":"BMJ Open"},{"issue":"6","key":"1351_CR85","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00130404-200511000-00002","volume":"11","author":"R Yancik","year":"2005","unstructured":"Yancik R. Population aging and cancer: a cross-national concern. Cancer J. 2005;11(6):437\u201341.","journal-title":"Cancer J"},{"issue":"2","key":"1351_CR86","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejpain.2004.07.011","volume":"9","author":"OHG Wilder-Smith","year":"2005","unstructured":"Wilder-Smith OHG. Opioid use in the elderly. Eur J Pain. 2005;9(2):137\u201340.","journal-title":"Eur J Pain"},{"issue":"3","key":"1351_CR87","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/psyg.12658","volume":"21","author":"S Chiappini","year":"2021","unstructured":"Chiappini S, et al. Opioid painkiller dependence in a sample of elderly medical inpatients. Psychogeriatrics. 2021;21(3):265\u201371.","journal-title":"Psychogeriatrics"},{"key":"1351_CR88","unstructured":"Olthoff MV, et al. Overgevoeligheid voor hulpstoffen in pleisters. Nederlands Tijdschrift voor Geneeskunde; 2019. p. 163."},{"key":"1351_CR89","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.618411","volume":"12","author":"MS Alqahtani","year":"2021","unstructured":"Alqahtani MS, et al. Advances in oral drug delivery. Front Pharmacol. 2021;12: 618411.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1351_CR90","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1600-0536.2008.01472.x","volume":"59","author":"K Vander Hulst","year":"2008","unstructured":"Vander Hulst K, et al. Allergic contact dermatitis from transdermal buprenorphine. Contact Dermat. 2008;59(6):366\u20139.","journal-title":"Contact Dermat"},{"issue":"1","key":"1351_CR91","first-page":"5","volume":"90","author":"P Romita","year":"2018","unstructured":"Romita P, et al. Contact dermatitis due to transdermal therapeutic systems: a clinical update. Acta Biomed. 2018;90(1):5\u201310.","journal-title":"Acta Biomed"},{"key":"1351_CR92","doi-asserted-by":"crossref","unstructured":"Chiappini S., et al., Pharmacovigilance signals of the opioid epidemic over 10 years: data mining methods in the analysis of pharmacovigilance datasets collecting adverse drug reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). Pharmaceuticals (Basel). 2022;15(6).","DOI":"10.3390\/ph15060675"},{"key":"1351_CR93","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.forsciint.2014.10.028","volume":"245","author":"M H\u00e4kkinen","year":"2014","unstructured":"H\u00e4kkinen M, Vuori E, Ojanper\u00e4 I. Prescription opioid abuse based on representative postmortem toxicology. Forensic Sci Int. 2014;245:121\u20135.","journal-title":"Forensic Sci Int"},{"key":"1351_CR94","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","volume":"106","author":"SD Comer","year":"2019","unstructured":"Comer SD, Cahill CM. Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev. 2019;106:49\u201357.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"1351_CR95","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1526-4637.2008.00413.x","volume":"9","author":"AB O'Connor","year":"2008","unstructured":"O\u2019Connor AB. Is actiq use in noncancer-related pain really \u201ca recipe for success\u201d? Pain Med. 2008;9(2):258\u201360.","journal-title":"Pain Med"},{"issue":"2","key":"1351_CR96","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1526-4637.2006.00295.x","volume":"8","author":"SD Passik","year":"2007","unstructured":"Passik SD, Kirsh KL. Weighing in on the off-label use of Actiq\u2122 for noncancer-related pain: a recipe for success or a recipe for disaster? Pain Med. 2007;8(2):130\u20133.","journal-title":"Pain Med"},{"key":"1351_CR97","unstructured":"Carreyrou J. Narcotic \u2018lollipop\u2019is big seller despite FDA curbs. Wall Street J; 2006:735399\u2013114."},{"key":"1351_CR98","volume-title":"Withdrawal Assessment report: Effentora","author":"European Medicines Agency","year":"2013","unstructured":"European Medicines Agency. Withdrawal Assessment report: Effentora. Amsterdam: European Medicines Agency; 2013."},{"key":"1351_CR99","volume-title":"Questions and answers, Withdrawal of the application for a change to the marketing authorisation for Effentora (fentanyl)","author":"European Medicines Agency","year":"2013","unstructured":"European Medicines Agency. Questions and answers, Withdrawal of the application for a change to the marketing authorisation for Effentora (fentanyl). Amsterdam: European Medicines Agency; 2013."},{"key":"1351_CR100","unstructured":"Takeda Pharma A\/S. Instanyl 50 micrograms\/dose nasal spray, solution SmPC. 2009. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/instanyl-epar-product-information_en.pdf."},{"key":"1351_CR101","unstructured":"Teva B.V. Effentora 100 micrograms buccal tablets. 2008. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/effentora-epar-product-information_en.pdf."},{"issue":"3","key":"1351_CR102","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40264-020-01020-4","volume":"44","author":"P Jain","year":"2021","unstructured":"Jain P, et al. Evaluation of opioid overdose reports in patients treated with extended-release naltrexone: postmarketing data from 2006 to 2018. Drug Saf. 2021;44(3):351\u20139.","journal-title":"Drug Saf"},{"issue":"8","key":"1351_CR103","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/archdischild-2019-317933","volume":"105","author":"C Ekhart","year":"2020","unstructured":"Ekhart C, de Vries T, van Hunsel F. Psychiatric adverse drug reactions in the paediatric population. Arch Dis Child. 2020;105(8):749\u201355.","journal-title":"Arch Dis Child"},{"issue":"5","key":"1351_CR104","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions\u202f: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"5","key":"1351_CR105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","volume":"16","author":"JJ Coleman","year":"2016","unstructured":"Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Lond). 2016;16(5):481\u20135.","journal-title":"Clin Med (Lond)"},{"issue":"2","key":"1351_CR106","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/S2468-2667(21)00254-1","volume":"7","author":"D Lewer","year":"2022","unstructured":"Lewer D, et al. Causes of death among people who used illicit opioids in England, 2001\u201318: a matched cohort study. Lancet Public Health. 2022;7(2):e126\u201335.","journal-title":"Lancet Public Health"},{"issue":"1","key":"1351_CR107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/21556660.2019.1566137","volume":"8","author":"MD G\u00fcner","year":"2019","unstructured":"G\u00fcner MD, Ekmekci PE. Healthcare professionals\u2019 pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. J Drug Assess. 2019;8(1):13\u201320.","journal-title":"J Drug Assess"},{"issue":"3","key":"1351_CR108","doi-asserted-by":"crossref","first-page":"931","DOI":"10.18549\/PharmPract.2017.03.931","volume":"15","author":"E Cheema","year":"2017","unstructured":"Cheema E, et al. Barriers to reporting of adverse drugs reactions: a cross sectional study among community pharmacists in United Kingdom. Pharm Pract (Granada). 2017;15(3):931.","journal-title":"Pharm Pract (Granada)"},{"key":"1351_CR109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40267-023-01000-5","volume":"39","author":"J Joaquim","year":"2023","unstructured":"Joaquim J, et al. All-round approaches to increase adverse drug reaction reports: a scoping review. Drugs & Therapy Perspectives. 2023;39:249\u201361.","journal-title":"Drugs & Therapy Perspectives."},{"key":"1351_CR110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s40267-017-0380-3","volume":"33","author":"C Matos","year":"2017","unstructured":"Matos C, Rodrigues L, Joaquim J. Attitudes and opinions of Portuguese community pharmacy professionals towards patient reporting of adverse drug reactions and the pharmacovigilance system. Drugs Ther Perspect. 2017;33:188\u201394.","journal-title":"Drugs Ther Perspect."},{"issue":"1","key":"1351_CR111","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/ijd.IJD_579_17","volume":"63","author":"S Pande","year":"2018","unstructured":"Pande S. Causality or relatedness assessment in adverse drug reaction and its relevance in dermatology. Indian J Dermatol. 2018;63(1):18\u201321.","journal-title":"Indian J Dermatol"},{"key":"1351_CR112","doi-asserted-by":"crossref","unstructured":"Wallerstedt SM, G Brunl\u00f6f, A. Sundstr\u00f6m. Rates of spontaneous reports of adverse drug reactions for drugs reported in children. Drug Saf. 2011;34(8):669\u201382.","DOI":"10.2165\/11591730-000000000-00000"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01351-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01351-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01351-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:33:14Z","timestamp":1730313194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01351-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":112,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1351"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01351-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"11 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Moa Gustaffson, Cristiano Matos, Jo\u00e3o Joaquim, Joep Scholl and Florence van Hunsel have no conflicts of interest to declare that are directly relevant to the contents of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not needed for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No approval or consent was needed for this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No approval or consent was needed for this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets for this manuscript are not publicly available due to the data protection policy of the Pharmacovigilance Centre Lareb. Requests to access the datasets should be directed to the first author and will be granted on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The SQL statements for the data used in this article are not publicly available due to the data protection policy of Lareb. Requests to access the datasets should be directed to the first author and will be granted on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The original study protocol was designed by MG and CM with input from FvH. JS established the query and dataset. Data analysis was performed by MG and CM, and the design of the manuscript was determined by all authors. All authors contributed to the final data analysis and manuscript drafting and revision. All authors approved the final version to be published and agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"All personal data from the patient\u2019s reporting form is handled in accordance with the General Data Protection Regulation (GDPR) and the general privacy regulation of the Pharmacovigilance Centre Lareb.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Privacy statement"}}]}}